Human medicines European public assessment report (EPAR): Fulvestrant Mylan, fulvestrant, Date of authorisation: 08/01/2018, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Emgality, galcanezumab, Date of authorisation: 14/11/2018, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Zeposia, ozanimod, Date of authorisation: 20/05/2020, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Gardasil 9, human papillomavirus 9-valent vaccine (recombinant, adsorbed), Date of authorisation: 10/06/2015, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Scemblix, asciminib, Date of authorisation: 25/08/2022, Revision: 12, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Nasym, bovine respiratory syncytial virus vaccine (live), Status: Authorised

Veterinary medicines European public assessment report (EPAR): MS-H Vaccine, Mycoplasma synoviae (live), Status: Authorised

Veterinary medicines European public assessment report (EPAR): Mirataz, mirtazapine, Status: Authorised

Human medicines European public assessment report (EPAR): Adasuve, loxapine, Date of authorisation: 20/02/2013, Revision: 15, Status: Authorised

Annual report of the Pharmacovigilance Inspectors Working Group for 2024